Home › Funds › ACUTA CAPITAL PARTNERS, LLC › ERAS
ACUTA CAPITAL PARTNERS, LLC position in ERAS
ERASCA INC · Health Care
ACUTA CAPITAL PARTNERS, LLC reported holding 265,199 shares of ERAS (ERASCA INC) in its Q2 2026 13F filing — a position valued at US$4.9M, representing 3.39% of its reported portfolio and ranking #9 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed ERAS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ACUTA CAPITAL PARTNERS, LLC's ERAS position evolved
ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in ERAS in Q1 2026 at 354,575 shares (US$5.7M). Across 2 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 265,199 shares valued at US$4.9M — a reduction of -89,376 shares quarter over quarter.. Notable position changes include a 25% trim in Q2 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 354.57K | $5.74M | New |
| Q2 2026 | 265.20K | $4.86M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ERAS and 13F data
ERAS (ERASCA INC) is a Health Care company. 79 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$457.5M), RTW INVESTMENTS, LP (US$328.8M), Venrock Adviser, LLC (US$327.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ERAS
- Frazier Life Sciences Management, L.P. 24.98M sh · $457.55M · Q2 2026
- RTW INVESTMENTS, LP 17.95M sh · $328.78M · Q2 2026
- Venrock Adviser, LLC 17.89M sh · $327.78M · Q2 2026
- Logos Global Management LP 12.15M sh · $222.59M · Q2 2026
- Siren, L.L.C. 11.40M sh · $208.81M · Q2 2026
- Paradigm Biocapital Advisors LP 9.55M sh · $174.96M · Q2 2026
- ARCH Venture Management, LLC 7.09M sh · $129.92M · Q2 2026
- Cormorant Asset Management, LP 6.00M sh · $109.92M · Q2 2026
- Affinity Asset Advisors, LLC 5.25M sh · $96.18M · Q2 2026
- Vivo Capital, LLC 4.13M sh · $75.61M · Q2 2026
- a16z Capital Management, L.L.C. 2.86M sh · $52.44M · Q2 2026
- Soleus Capital Management, L.P. 2.70M sh · $49.46M · Q2 2026
More on ACUTA CAPITAL PARTNERS, LLC
FAQ
How long has ACUTA CAPITAL PARTNERS, LLC held ERAS?
ACUTA CAPITAL PARTNERS, LLC has disclosed ERAS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is ACUTA CAPITAL PARTNERS, LLC's current position in ERAS?
As of Q2 2026, ACUTA CAPITAL PARTNERS, LLC holds 265.20K shares of ERAS (ERASCA INC), valued at $4.86M, representing 3.39% of its reported portfolio and ranking #9.
Has ACUTA CAPITAL PARTNERS, LLC been buying or selling ERAS?
In the latest 13F filing (Q2 2026), ACUTA CAPITAL PARTNERS, LLC reduced its position in ERAS.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 79 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.